Transforming growth factor beta (TGF-b) has an important role in mediating T-cell suppression in B-cell non-Hodgkin lymphoma (NHL). However, the underlying mechanism responsible for TGF-b-mediated inhibition of effector memory T (T m ) cells is largely unknown. As reported here, we show that exhaustion is a major mechanism by which TGF-b inhibits T m cells, and TGF-b mediated exhaustion is associated with upregulation of CD70. We found that TGF-b upregulates CD70 expression on effector T m cells while it preferentially induces Foxp3 expression in naive T cells. CD70 induction by TGF-b is Smad3-dependent and involves IL-2/Stat5 signaling. CD70 þ T cells account for TGF-b-induced exhaustion of effector T m cells. Both TGF-b-induced and preexisting intratumoral CD70 þ effector T m cells from B-cell NHL have an exhausted phenotype and express higher levels of PD-1 and TIM-3 compared with CD70 À T cells. Signaling transduction, proliferation and cytokine production are profoundly decreased in these cells, and they are highly susceptible to apoptosis. Clinically, intratumoral CD70-expressing T cells are prevalent in follicular B-cell lymphoma (FL) biopsy specimens, and increased numbers of intratumoral CD70 þ T cells correlate with an inferior patient outcome. These findings confirm TGF-b-mediated effector T m cell exhaustion as an important mechanism of immune suppression in B-cell NHL.
INTRODUCTION
T-cell exhaustion is a type of immune response describing the condition in which T cells exhibit reduced differentiation, proliferation and effector function. T-cell exhaustion is initially recognized and characterized in chronic viral infections. [1] [2] [3] [4] [5] [6] [7] In tumors, it has been observed that intratumoral T cells display a phenotypic and functional profile similar to that of exhausted T cells from chronic viral infection. [8] [9] [10] Phenotypically, PD-1 expression has been demonstrated to be a marker to identify exhausted T cells in viral infection 3, 4 and tumors. 11, 12 Recently, we found that interleukin (IL)-12 induces T-cell exhaustion through upregulating TIM-3 in patients with follicular lymphoma (FL). 13 Co-stimulatory molecule CD70 can be expressed on T cells upon T-cell receptor stimulation.
14 CD70 expression causes a change in T-cell function, 15 and high levels of CD70 have been shown to be involved in the pathophysiology of several diseases. [16] [17] [18] Over the recent decades, efforts to explore the underlying mechanism of CD70 upregulation on T cells have proved difficult. 19 Studies have suggested that DNA methylation of the CD70 promoter gene has an important role in CD70 upregulation on T cells in various autoimmune diseases. 20, 21 However, it is not known which cytokine can upregulate CD70 expression on T cells.
Cytokine transforming growth factor beta (TGF-b) exerts the greatest impact on T cells by inhibiting their activation, proliferation, differentiation and survival. 22, 23 B cells, including malignant B cells, are a source of inhibitory cytokines such as IL-10 and TGF-b, suggesting a role for TGF-b in B-cell NHL. 24 An important question arises about which type of response is responsible for TGFb-mediated suppression of effector memory T (T m ) cells. Several studies have implied that TGF-b may induce T-cell exhaustion that leads to a declined T-cell proliferation and function as well as enhanced cell death. [25] [26] [27] However, the underlying mechanism, especially which subpopulation contributes to TGF-b-mediated T-cell inhibition possibly by T-cell exhaustion, is unknown.
In the present study, we have identified TGF-b to be a key regulator of CD70 expression on T cells. We then determined the phenotypical and functional changes of TGF-b-induced or intratumoral preexisting CD70 þ T cells as well as the clinical impact of CD70-expressing T cells on patient outcome in FL. The data we present in this study demonstrate the biological and clinical significance of TGF-b-mediated CD70 induction and the subsequent inhibition of T m cell function.
MATERIALS AND METHODS

Patient samples
Patients providing written informed consent were eligible for this study if they had a tissue biopsy that on pathological review showed follicular B-cell NHL and adequate tissue or peripheral blood to perform the experiments. Peripheral blood mononuclear cells from healthy donors and normal specimens from patients with follicular hyperplasia were used as controls. The use of human tissue samples for this study was approved by the Institutional Review Board of the Mayo Clinic/Mayo Foundation.
Cell isolation and culture
Fresh tumor biopsy specimens from patients with FL and control lymph nodes (LNs) were gently minced over a wire mesh screen to obtain a cell suspension. The cell suspension or peripheral blood from patients or healthy donors was centrifuged over Ficoll-Hypaque at 500 g for 15 min to isolate mononuclear cells. CD3 þ , CD4 þ , CD8 þ T cells and CD19 þ B cells were isolated using positive selection with CD3, CD4, CD8 or CD19 microbeads (Miltenyi Biotec, Auburn, CA, USA).
Ab-activated T cells unless otherwise noted as resting cells. CD4 þ T cells were used in the majority of experiments.
Intracellular staining
Cells were washed and subjected to fixation, permeabilization, stained with fluorochrome-conjugated antibodies and analyzed by flow cytometry. For cytokine induction, we cultured CD4 þ T cells in anti-CD3-coated plates and treated with or without stimuli for 3 days. Cells were restimulated with phorbol myristate acetate (PMA)/Ion plus Brefeldin A for 4 h and analyzed by flow cytometry. For cytokine production by intratumoral T cells, we stimulated cells with PMA/Ion plus Brefeldin A for 4 h and analyze by flow cytometry. Foxp3 expression was determined using Foxp3 detection kit (Biolegend, San Diego, CA, USA) following the manufacturer's instructions. For Ki-67 expression, cells were incubated with 70% ethanol for 1 h, stained with Ki-67-APC Ab and analyzed by flow cytometry.
Enzyme-linked immunosorbent assay
Concentration of soluble CD27 in experimental supernatants was measured using an Instant enzyme-linked immunosorbent assay kit from eBioscience (San Diego, CA, USA; no. BMS286INST). For each sample, 50 ml were done in duplicate and incubated for 3 h at room temperature on rotary shaker. After washing the micro wells, 100 ml TMB Substrate was added to each well and color was allowed to develop for 10 min. Reaction was stopped by adding 100 ml of Stop Solution, and the plate was read immediately on a SpectraMax 190 plate reader (Sunnyvale, CA, USA) at 450 nm using the SoftMax Pro software program (Sunnyvale, CA, USA).
Signal transducer and activator of transcription factor 5 (Stat5) phosphorylation assay
The phosphorylation of Stat5 was detected following the manufacturer's instructions (BD Biosciences, San Jose, CA, USA). Briefly, fresh isolated mononuclear cells from biopsy specimens of patients with B-cell NHL were incubated with IL-2 (50 ng/ml) for 30 min, then fixed and permeabilized using a phosflow kit (BD Biosciences). Cells were stained with anti-pStat5-Alexa647 Ab plus anti-CD3-FITC and CD70-PE antibodies for 30 min and analyzed by flow cytometry.
Small interfering RNA (siRNA) transfection
Transfection of CD4
þ T cells with siRNA was performed according to the manufacturer's instruction (Qiagen, Cambridge, MA, USA). Genesolution siRNA and Hiperfect Transfection Reagent were purchased from Qiagen. In all, 100 nM siRNA for CD70 or Stat5 or a scrambled siRNA was transfected in a 24-well tissue culture plate for 24 h. After washing, cells were cultured in OKT3-coated plate in the presence or absence of TGF-b 50 ng/ml for 3 days, and CD70 expression was measured by flow cytometry.
Statistical analysis
Statistical analysis was performed using the Student's t-test. Significance was determined at Po0.05. Overall survival was measured from the date of diagnosis until death from any cause. Patients alive and still at risk of death at last follow-up evaluation were censored for the analysis of overall survival. Survival of all patients was estimated using the Kaplan-Meier method. The univariate association between CD70 expression and survival was determined with the log-rank test.
RESULTS
TGF-b induces CD70 expression on T cells
We have recently shown that TGF-b has a critical role in mediating T-cell differentiation in the tumor microenvironment of B-cell NHL. 24, 28 To further evaluate the role of TGF-b on immune responses, we determined the effect of TGF-b on the expression of various cell surface markers, cytokines, transcription factors and signaling molecules in intratumoral T cells derived from patients with B-cell NHL using flow cytometry ( Figure 1a ). As expected, TGF-b inhibited the expression of most of the cell surface and signaling molecules tested. However, TGF-b increased expression of three molecules, one of which was Foxp3, which is well known to be upregulated by TGF-b. Consistent with previous reports, TGF-b also increased IL-2 expression. 29, 30 Surprisingly, the expression of CD70 was dramatically enhanced on T cells following treatment with TGF-b ( Figure 1a ). CD70 is normally absent on resting T cells and is induced upon activation (Supplementary Figure S1A) . With the addition of TGF-b, CD70 expression on activated T cells is significantly upregulated (Figure 1b) . TGF-b not only increased the number of T cells expressing CD70 but also enhanced the magnitude of CD70 expression on T cells in a dose-and time-dependent manner (Figures 1b-e) .
To determine whether CD70 upregulation was specific to TGF-b, we tested a panel of cytokines for their capacity to upregulate CD70 expression. Among the 12 tested, TGF-b remained the only cytokine that strongly induced CD70 expression (Supplementary Figure S1B) . Although a previous study has reported that IL-2 upregulates CD70 expression on CD8 þ T cells in mice, 15 we found that CD70 expression was not upregulated on human T cells treated with IL-2 alone, and the addition of IL-2 had no further impact on TGF-b-mediated induction of CD70 on activated T cells (Supplementary Figure S2) .
We next determine whether TGF-b was able to upregulate CD70 expression on activated B cells or monocytes. As shown in supplementary Figure S3 , although activation through lipopolysaccharide, but not CD40L, enhanced CD70 expression, TGF-b was unable to upregulate CD70 expression on either CD19 þ or CD11c þ cells. In fact, treatment with TGF-b was associated with a slight decrease in CD70 expression on both resting and activated CD19 þ or CD11c þ cells (Supplementary Figure S3) . These results indicate that TGF-b-induced CD70 expression is specific to T cells.
It is well known that TGF-b induces the expression of Foxp3, a transcriptional factor critically important for regulatory T cells. Thus, we examined the induction of Foxp3 and CD70 in activated Figure S4 ). Namely, in T n cells, TGF-b had a greater effect on Foxp3 induction than CD70. In contrast, TGF-b-mediated CD70 upregulation was more profound than that of Foxp3 in T m cells (Figure 2g ). These results suggest that TGF-b differentially exerts its function on T n and T m cells.
IL-2/Stat5 signaling is involved in TGF-b-mediated CD70 induction in T cells
As Smad3 activation is a key component of the TGF-b signaling pathway, we first determined the role of Smad3 in TGF-bmediated CD70 induction using a specific Smad3 inhibitor SIS3.
Activated CD4
þ T cells treated with SIS3 alone showed no effect on CD70 expression (Figure 3a) . However, CD70 induction by TGF-b was completely blocked when T cells were treated with 5 mg/ml SIS3. This result suggests that TGF-b-induced CD70 expression is Smad3 dependent.
Given that TGF-b induces IL-2 production, we next tested whether IL-2 signaling is involved in TGF-b-mediated CD70 induction. Although addition of exogenous IL-2 had no effect on CD70 induction, we observed that IL-2 depletion by an anti-IL-2 Ab led to complete inhibition of CD70 induction on T cells activated with T-cell receptor stimulation (Figure 3b ). This depletion also attenuated TGF-b-mediated CD70 induction on T cells although CD70 upregulation was not completely blocked ( Figure 3b ). We observed that this attenuation was more pronounced in T n than in T m cells and affected both CD70 and Foxp3 upregulation by TGF-b (Figure 3c , Supplementary Figure S4) . These results suggest that IL-2 signaling is essential for activation-induced CD70 expression and also has a role in TGF-b-mediated CD70 induction.
Although activation is required, TGF-b-induced CD70 expression may occur through a different pathway. Although the vast majority of CD70-expressing cells are CD25 þ or Ki-67 þ activated T cells, only a subset of CD25 þ or Ki-67 þ T cells were able to respond to TGF-b and upregulate CD70 expression (Figure 3d) . However, the expression of CD25 or Ki-67 was inhibited in CD4 þ T cells treated with TGF-b (Figures 3d and 4a) . The association between increased CD70 expression and downregulated CD25 or Ki-67 suggests that TGF-b-mediated CD70 enhancement is not simply due to T-cell activation.
It has been shown that Stat5 activation has a crucial role in TGFb-mediated induction of Foxp3 in T cells. 31 Given the similar effect of TGF-b on CD70 expression, we wondered whether Stat5 was also involved in CD70 induction by TGF-b. To test this, we transfected Stat5 siRNA into CD4 þ T cells and monitored CD70 expression. We observed that TGF-b-mediated CD70 induction was attenuated when activated T cells were transfected with Stat5 siRNA (Figure 3e ). To further confirm the role of IL-2/Stat5 signaling in TGF-b-mediated CD70 induction, we treated T cells with the calcineurin inhibitor cyclosporin A (CsA) and mammalian target of rapamycin inhibitor Rapamycin (Rapa), which block nuclear factor of activated T-cell activation and suppress IL-2/Stat5 signaling. As shown in Figures 3f and g, both CsA and Rapa were able to inhibit activation-induced CD70 expression on activated T cells in a dose-dependent manner. Furthermore, in the presence of either CsA or Rapa, TGF-b mediated induction of CD70 on activated T cells was no longer observed.
Supporting the above findings, we also observed that IL-2/Stat5 signaling was positively associated with CD70 expression in two T-cell lines, Jurkat and Karpas 299 (Supplementary Table S1 ). Karpas 299 cells, which constitutively express CD70 on the cell surface, respond to IL-2 with subsequent activation of Stat5. In contrast, Jurkat cells do not express surface CD70 nor respond to IL-2. Similarly, IL-2 receptor a is expressed on Karpas 299 cells and is absent on Jurkat cells. Taken together, these data indicate that IL-2/Stat5 signaling has a role in TGF-b-mediated CD70 expression on T cells.
CD70
þ T cells express exhaustion markers PD-1 and TIM-3
To phenotypically characterize CD70 þ T cells, we measured the expression of an array of surface markers on resting CD70 þ T cells isolated from specimens of FL patients (Figure 4a ). Intratumoral CD70 þ T cells expressed high levels of CD45RO, indicating that the cells were T m cells. Although the majority of CD70 þ T cells are CD27 þ and CD28 þ , the loss of CD27 and CD28 was substantial. Most CD8 þ CD70 þ and some CD4 þ CD70 þ T cells expressed PD-1 and TIM-3. Therefore we compared the expression of PD-1 and TIM-3 between CD4 þ CD70 À and CD4 þ CD70 þ T cells. We found that both TGF-b-induced and preexisting CD70 þ T cells express significantly higher levels of PD-1 and TIM-3 compared with CD70 À T cells (Figure 4b ), Supporting this finding, TGF-b treatment upregulated PD-1 expression on T cells while no similar effects can be seen by other cytokines (Figure 4c ). TGF-b-mediated PD-1 upregulation was mainly seen on CD70 þ T cells (Figure 4d ). Although TGF-b treatment caused downregulation of TIM-3 (Figure 4c ), CD70
À T cells accounted for the majority of this downregulation (Figure 4d ). The majority of CD70 þ T cells maintained TIM-3 expression on the cell surface. These results implied that CD70 þ T cells are exhausted cells.
þ T cells treated with TGF-b displayed decreased expression of the activation markers CD25 and Ki-67 as well as reduced proliferation as indicated by decreased numbers of CFSE dim cells (Figure 5a ). TGF-b also inhibited interferon (IFN)-g production but enhanced IL-2 expression by CD4 þ T cells (Figure 5b ). Given that TGF-b upregulates CD70 expression, we tested whether CD70 induction has a role in mediating the effects of TGF-b on T cells. As shown in Figure 5c , CD4 þ CD70 þ T cells were the major population responsible for IFN-g production, and TGF-b treatment significantly reduced IFN-g expression by CD70 þ T cells. Although both CD70 þ and CD70 À T cells were able to produce IL-2, IL-2 production was more profoundly enhanced in TGF-b-induced CD70 þ cells than in CD70 À T cells. These results suggest that CD70 induction accounts for TGF-b-mediated effects on CD4 þ T cells. To further functionally characterize CD70
þ T cells, we measured cytokine production as well as Stat phosphorylation in CD70 þ T cells isolated from biopsy specimens of lymphoma patients. As shown in Figure 5d , intratumoral CD70 À T cells were predominantly the source of cytokine production, whereas CD70 þ T cells failed to produce cytokines when stimulated with PMA/Ion. Next, we determined whether signal transduction was also inhibited in CD70 þ T cells. Intratumoral T cells were treated with or without IL-2, and Stat5 phosphorylation was measured in CD70
À or CD70 þ T cells. We found that a subpopulation of intratumoral T cells were able to respond to IL-2 with subsequent activation of Stat5. However, CD70
À T cells accounted for this response, whereas CD70 þ T cells completely lacked the capacity (Figure 5e ).
Exhausted CD70
þ T cells are highly susceptible to apoptosis TGF-b is known to induce apoptosis in a variety of cell types. We observed that treatment with TGF-b induces apoptosis of B cells and results in a significant decrease in cell number of both resting and lipopolysaccharide-or CD40L-activated B cells during shortterm culture (3 days) (Supplementary Figure S5A) . However, we failed to see a decrease in cell number of either resting or activated T cells during the same period of culture (Supplementary Figure S5B) . When we measured apoptosis, TGF-b treatment had no effect on CD4 þ T-cell apoptosis for the first several days (Supplementary Figure S5C) , which is consistent with previous studies. However, upon extended culture, TGF-b eventually led to a decreased viability of T cells (Figure 6a ). This late-onset effect suggests that other earlier changes in T cells by TGF-b are necessary for the cells to become susceptible to apoptotic induction. Therefore we tested whether CD70 induction contributes to the late-onset TGF-b-induced apoptosis in CD4 þ T cells. Indeed, we found that CD70 þ T cells displayed a significantly higher rate of apoptosis than CD70 À T cells.
Treatment with TGF-b did not induce apoptosis in activated CD70
À T cells but increased apoptosis in activated CD70 þ T cells (Figure 6b ). This finding was further supported by the observation that the increased number of CD70 þ T cells, induced by Figure S6) . This is in line with the 
CD27-CD70 interaction contributes to TGF-b-induced T-cell exhaustion
To investigate whether CD27-CD70 interaction has a role in TGFb-induced T-cell exhaustion, we first determined the expression of CD27 on CD4 þ T cells treated with or without TGF-b, as it has been shown that CD70 expression is associated with CD27 downregulation on T cells. 18 We observed that TGF-b downregulated CD27 expression on the surface CD4 þ T cells and resulted in an increase in the number of CD70 þ CD27 À T cells (Figures 7a and b) . Because it has been well known that CD27 can be cleaved from the cell surface, we next tested whether TGFb-induced CD27 downregulation is due to shedding of surface CD27, resulting in elevated levels of soluble CD27. As shown in Figure 6c , although culture medium had no soluble CD27, activated T cells shed CD27 into culture medium at a time-dependent manner. Treatment with TGF-b resulted in a significant increase in soluble CD27 (Figure 7c ). In the presence of an anti-CD70 Ab, the TGF-b-induced increase in soluble CD27 level was attenuated (Figure 7d ). Concomitant with soluble CD27 levels, the TGF-bmediated decrease in surface CD27 expression was inhibited by treatment with the anti-CD70 Ab (Figure 7e ). These results suggested that while cleavage contributes to surface CD27 downregulation, CD70 upregulation might be responsible for TGF-b-mediated shedding of CD27 from T cells.
Next, we determined whether CD27/CD70 signaling has a role in TGF-b-mediated T-cell exhaustion by blocking the CD27/CD70 interaction. As shown in Figure 7f , while TGF-b treatment showed a modest inhibition of IFN-g production on day 1, prolonged incubation with TGF-b significantly suppressed IFN-g production by CD4
þ T cells on day 7. Treatment with a blocking anti-CD70 Ab alone slightly inhibited IFN-g expression by CD4
þ T cells. However, in the presence of the CD70 Ab, TGF-b-mediated inhibition was attenuated on day 7 (Figure 7f) . Similarly, while TGF-b alone inhibited Ki-67 expression in CD4 þ T cells, this inhibition was reduced in the presence of the blocking anti-CD70 Ab on day 7 (Figure 7g ). These results suggest that CD27/CD70 interaction is involved in TGF-b-mediated T-cell exhaustion.
The frequency of CD70
þ T cells is associated with a poor outcome in FL patients Because lymphoma-associated CD70-expressing T cells were functionally incompetent, we predicted that intratumoral CD70 T cells would adversely affect patient outcomes in B-cell NHL. We first measured the numbers of CD70 þ T cells in biopsy specimens from a cohort of 32 untreated FL patients. The specimens from LNs of patients with follicular hyperplasia were used as a control. The biopsy specimens from FL patients were collected at diagnosis with variable histological grades (g1: 17 patients; g2: 7 patients; g3a: 8 patients). Many patients were initially observed, but all patients subsequently received chemotherapy in combination with rituximab as therapy for the disease. CD70 was highly expressed on a subset of T cells from LNs from FL patients, whereas its expression was negligible or low on T cells from benign LNs (Figure 8a ). On average, the number of CD70 þ T cells accounted for 11.32±1.248% of CD3 þ T cells in LNs of FL patients (range: 1.9-28.5%, n ¼ 32) as compared with 5.1 ± 1.9 in healthy tissue (range: 1.3-21.0%, n ¼ 10, P ¼ 0.016) (Figure 8b ). In addition to flow cytometry, we did immunohistochemistry to determine CD70 expression in FL specimens (Figure 8c , top panel). Tonsil tissues were stained as a control. We found that CD70 was brightly stained in cells within follicles (B-cell region) as well as cells from interfollicle areas (T-cell region). In contrast, CD70 staining in tonsil was modest with dim staining of a few cells within follicles. To further topographically identify CD70 þ T cells in FL tissue, we sequentially stained the same tissue section for CD70, CD20 and CD3 and visualized co-expression of these antigens using a novel method devised by Glass et al. 32 The resulting images captured were overlaid, and each antigen assigned a color using Adobe Photoshop CS2 (Adobe Systems, Inc., San Jose, CA, USA). As shown in Figure 8c (bottom), CD70 staining (red) was seen in both the intra-and extra-follicular regions and was co-expressed with CD20 (yellow, mostly intra-follicular) and CD3 (blue, mostly extrafollicular). These results were consistent with the flow cytometry results. To test whether elevated numbers of CD70 þ T cells had an impact on patient outcome, we performed a Kaplan-Meier analysis to correlate the number of intratumoral CD70
þ T cells at diagnosis with overall survival in a cohort of FL patients who all received chemotherapy and rituximab during their disease course. Using the median of 11% of CD70 þ T cells as a cutoff, we found that higher numbers of CD70 þ T cells were significantly associated with a shorter overall survival in FL patients (Figure 8d ).
DISCUSSION
The mechanism by which CD70 expression is regulated remains largely unstudied, and little is known about cytokine regulation of CD70 expression on T cells. Non-specific activation of T cells is able to upregulate CD70 expression, but the extent of the upregulation is modest. In the presence of TGF-b, however, we find that CD70 expression levels are significantly increased. This induction was specific; none of other cytokines tested was able to regulate CD70 expression on T cells, including IL-2, which has been shown by others to upregulate CD70 expression on CD8 þ T cells in patients with metastatic melanoma. 33 We have shown that the Smad signaling pathway is required and that Stat5 signaling also has an important role although the predominant effect of IL-2/Stat5 signaling was seen in naive T cells. This is in agreement with the finding that Stat5 signaling is essential for TGF-b-mediated Foxp3 induction in T cells. 31 The finding that CD70 and Foxp3 can be induced in either the same cells or in separate cells indicates that they may use unique signaling pathways when responding to TGF-b. Supporting this, we found that TGF-b predominantly upregulates CD70 expression on T m cells while Foxp3 expression is preferentially upregulated in T n cells. This finding is consistent with the result that IL-2/Stat5 signaling has a greater effect on TGF-b-mediated CD70 expression in naive T cells.
It was previously unclear how CD70 acquisition affects T-cell function. In this study, we observed that both TGF-b-induced and preexisting intratumoral CD70 þ T cells displayed phenotypic and functional changes similar to that in T-cell exhaustion. For example, CD70 þ T cells had higher PD-1 and TIM-3 expression compared with CD70 À T cells. The function of these cells was suppressed, and they exhibited reduced cytokine production and impaired signal transduction. Previous studies have suggested that TGF-b may induce T-cell exhaustion that leads to decreased T-cell proliferation and function. [25] [26] [27] However, the cell population responsible for this effect was unknown. The results we present in this study clearly show that CD70 upregulation is associated with TGF-b-induced exhaustion of effector T m cells.
Although TGF-b is known to induce apoptosis in a variety of types of cells, TGF-b-mediated apoptosis in T cells is only observed after extended culture. Studies have suggested that co-stimulation via CD28 has a crucial role in inhibiting TGF-b-induced apoptosis in T cells 34, 35 and may contribute to this late-onset apoptosis. We provide evidence that CD70 induction is responsible for this delayed TGF-b-mediated apoptosis. These exhausted CD70 þ T cells acquire more pro-apoptotic markers such as caspase-3 than CD70
À T cells and are more susceptible to activationinduced cell death.
Although we show that CD70 þ T cells are the major cell population contributing to TGF-b-mediated effects, it is unknown whether CD27/CD70 interaction has a role in TGF-b-induced T-cell exhaustion. Previous studies have shown that excessive or chronic CD27-CD70 signaling can lead to exhaustion in a murine model and results in impaired function of CD8 þ T cells. 15, 36, 37 Our finding that TGF-b-mediated downregulation of surface CD27 on CD70 þ T cells is due to shedding of CD27, creates a model whereby CD70 expression on T cells leads to stimulation (or overstimulation) of neighboring T cells (or auto-stimulation) through CD27 at which point CD27 is cleaved from the cell surface. We observed that blocking CD70 reverses CD27 loss on the cell surface and restores cell function, including IFN-g production and cell viability, confirming the role of CD27/CD70 interaction in TGF-b-mediated T-cell exhaustion.
The role of CD70-CD27 interaction in tumors is controversial. Although numerous studies suggest that CD70-CD27 interaction improves antitumor immunity, many other reports find the opposite. It has been shown that CD27 ligation by CD70-expressing tumor cells, 38, 39 genetically modified tumor cells expressing CD70, [40] [41] [42] [43] soluble CD70 [44] [45] [46] or agonistic anti-CD27 antibodies [47] [48] [49] induces an antitumor response by activating cytotoxic T lymphocytes and enhancing tumor-specific cytotoxicity. In contrast, it has been suggested that the CD70-CD27 interaction may favor immune escape through the development of intratumoral regulatory T cells, 50, 51 the promotion of lymphocyte apoptosis 48, 52, 53 or the depletion of natural killer cell. 36, 54 In B-cell malignancies, this discrepancy remains. Although CD70-CD27 interaction prevents T-cell anergy and enhances cytotoxic activity of tumor-specific cytotoxic T lymphocytes in acute lymphoblastic leukemia, 39 high CD70 expression levels correlate to shorter overall survival in both the GCB and ABC subtypes in diffuse large B-cell lymphoma. 55 Our data suggest that when T cells acquire CD70 expression, they become exhausted cells and their function is impaired, which correlates with an inferior clinical outcome in FL patients.
In summary, CD70 þ T cells represent a subpopulation of immune cells that is functionally exhausted, and the presence of intratumoral CD70 þ T cells in FL impacts patient outcome. We, for the first time, identify TGF-b as the cytokine responsible for upregulation of CD70 expression on T cells, thereby inducing T-cell exhaustion via CD27-CD70 signaling. These findings describe a novel mechanism to account for TGF-b-mediated suppressive effects on T cells in FL patients.
